Drug Profile


Alternative Names: Beta-IFN/PCB; Phycocyanobilin/interferon-beta

Latest Information Update: 26 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Center for Genetic Engineering and Biotechnology
  • Developer Center for Genetic Engineering and Biotechnology; Heber Biotec
  • Class Interferons
  • Mechanism of Action Immunomodulators; Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Multiple sclerosis

Most Recent Events

  • 01 Dec 2014 Interferon-beta/phycocyanobilin is available for licensing as of 01 Dec 2014.
  • 01 Dec 2014 Preclinical trials in Multiple sclerosis in Cuba (unspecified route) prior to December 2014 (CIGB presentation, 2014-2015)
  • 10 Jan 2013 CIGB has patent protection for Interferon-beta/phycocyanobilin in world
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top